Skip to main content
  • Poster presentation
  • Open access
  • Published:

Lipid changes in patients receiving nevirapine (NVP) in combination with tenofovir/emtricitabine: results from the CCIAT trial


Highly effective antiretroviral (ARV) therapy has resulted in improved patient (pt) longevity, but many ARV regimens are associated with increases in blood lipid markers, raising concern with the potential for premature atherosclerosis and coronary artery disease. Prior studies with NVP in ARV-naïve pts noted an increase in low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), although less significant than the high-density lipoprotein cholesterol (HDL-C) increase. The contribution of the NRTI backbone to this effect was unclear.


To address this, 39 pts were randomly chosen to participate in a lipid substudy of the Cell Cycle Independent ARV Therapy (CCIAT) trial; pts (N = 54: 67% men, 95% African-American) received NVP 200 mg twice daily in combination with once-daily tenofovir/emtricitabine (TDF/FTC) 300/200 mg in this trial which was designed to investigate the efficacy and safety of this regimen.

Summary of results

At baseline, mean total cholesterol (TC), HDL-C, LDL-C, and TG were 168 mg/dL, 41 mg/dL, 94 mg/dL, and 165 mg/dL, respectively. Pts included in this analysis had statistically significant increases from baseline in mean HDL-C levels (+19.6 mg/dL, n = 27; p < 0.0001) and statistically significant decreases in mean triglyceride levels from baseline (-46.7, n = 27; p < 0.05) (See table in Figure 1). The increases in mean HDL-C were statistically significant regardless of baseline level (20–30 mg/dL, p = 0.01; 31–40 mg/dL, p = 0.0007; >40 mg/dL, p = 0.004). For example, 10 pts with HDL-C >40 mg/dL who reached week 96 experienced a mean increase from 48 to 75 mg/dL. From baseline to week 96, mean TG levels decreased by 84.4 mg/dL (n = 27; p = 0.0001). There were no clinically meaningful changes in the LDL-C and TC levels observed in this study.

figure 1

Figure 1


The combination of NVP plus TDF/FTC resulted in apparent positive effects on serum lipids, with an increase in HDL-C, decrease in TGs and little change in LDL-C and TC. This regimen might improve the cardiovascular risk profile of pts taking ARV therapy.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Davis, C., Talwani, R., Gilliam, B. et al. Lipid changes in patients receiving nevirapine (NVP) in combination with tenofovir/emtricitabine: results from the CCIAT trial. JIAS 11 (Suppl 1), P121 (2008).

Download citation

  • Published:

  • DOI: